COMT val158met influence on electroconvulsive therapy response in major depression

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 1, 2010, Pages 286-290

  Domschke, Katharina ^a   Zavorotnyy, Maxim ^a   Diemer, Julia ^a   Nitsche, Sarina ^a   Hohoff, Christa ^a   Baune, Bernhard T ^b   Deckert, Juergen ^c   Arolt, Volker ^a   Zwanzger, Peter ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b JAMES COOK UNIVERSITY   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

COMT; Dopamine; ECT; Gender; Pharmacogenetics; Polymorphism

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CATECHOL METHYLTRANSFERASE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALLELE; ARTICLE; CAUCASIAN; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; FEMALE; GENDER; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; METHIONINE; MIDDLE AGED; VALINE;

EID: 73949111992     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30949     Document Type: Article

References (30)

1. Andrade C, Srinivasamurthy GM, Vishwasenani A, Prakash GS, Srihari BS, Chandra JS. 2002. High but not low ECS stimulus intensity augments apomorphine-stimulated dopamine postsynaptic receptor functioning in rats. J ECT 18:80-83.
2. Anttila S, Huuhka K, Huuhka M, Illi A, Rontu R, Leinonen E, Lehtimäki T. 2008. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharm J 8:113-116.
3. Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. 2006. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 90:251-256.
4. Baghai TC, Marcuse A, BroschM, Schüle C, Eser D, Nothdurfter C, Steng Y, Noack I, Pietschmann K,Möller HJ, Rupprecht R. 2006. The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. World J Biol Psychiatry 7:82-90.
5. Baune BT, Hohoff C, Berger K, Neumann A, Mortensen S, Roehrs T, Deckert J, Arolt V, Domschke K. 2008. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 33:924-932.
6. Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate - A practical and powerful approach to multiple testing. J Roy Statist Soc B 57:289-300.
7. Boudikova B, Szumlanski C, Maidak B, Weinshilboum R. 1990. Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther 48:381-389.
8. Chen J, Lipska BK, Halim N,MaQD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, HermanMM,Apud J, Egan MF, Kleinman JE, Weinberger DR. 2004. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 75:807-821.
9. Cusin C, Serretti A, Lattuada E, Lilli R, Lorenzi C, Smeraldi E. 2002. Association study of MAO-A, COMT, 5-HT2A, DRD2, and DRD4 polymorphisms with illness time course in mood disorders. Am J Med Genet 114:380-390.
10. Domschke K, Freitag CM, Kuhlenbäumer G, Schirmacher A, Sand P, Nyhuis P, Jacob C, Fritze J, Franke P, Rietschel M, Garritsen HS, Fimmers R, Nöthen MM, Lesch KP, Stögbauer F, Deckert J. 2004. Association of the functional V158M catechol-O-methyl-transferase polymorphism with panic disorder in women. Int J Neuropsychopharmacol 7:183-188.
11. Domschke K, Ohrmann P, Braun M, Suslow T, Bauer J, Hohoff C, Kersting A, Engelien A, Arolt V, Heindel W, Deckert J, Kugel H. 2008. Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. Psychiatry Res 163:13-20.
12. FleckMP, Poirier-Littre MF, Guelfi JD, BourdelMC,Loo H. 1995. Factorial structure of the 17-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 92:168-172.
13. Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, Laor N, Rauchverger B, Kreinin A, PoyurovskyM,SchneidmanM,Modai I, Weizman R. 1999. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Mol Psychiatry 4:389-392.
14. FunkeB,MalhotraAK,FinnCT, PlocikAM,LakeSL,LenczT,DeRosseP,Kane JM, Kucherlapati R. 2005. COMT genetic variation confers risk for psychotic and affective disorders: A case control study. Behav Brain Funct 1:19.
15. Harrison PJ, Tunbridge EM. 2008. Catechol-O-methyltransferase (COMT): A gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 33:3037-3045.
16. Ishihara K, Sasa M. 1999. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 80:185-189.
17. Kunugi H, Vallada HP, Hoda F, Kirov G, Gill M, Aitchison KJ, Ball D, Arranz MJ, Murray RM, Collier DA. 1997.Noevidence for an association of affective disorders with high- or low-activity allele of catechol- Omethyltransferase gene. Biol Psychiatry 42:282-285.
18. Lachman HM, Morrow B, Shprintzen R, Veit S, Parsia SS, Faedda G, Goldberg R, Kucherlapati R, Papolos DF. 1996. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet 67:468-472.
19. Mann JJ. 1998. Neurobiological correlates of the antidepressant action of electroconvulsive therapy. J ECT 14:172-180.
20. Mannisto PT, Kaakkola S. 1999. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
21. Massat I, Souery D, Del-Favero J, Nothen M, Blackwood D, Muir W, Kaneva R, Serretti A, Lorenzi C, Rietschel M, Milanova V, Papadimitriou GN, Dikeos D, Van Broekhoven C, Mendlewicz J. 2005. Association between COMT (Val158Met) functional polymorphism and early onset in patients with major depressive disorder in a European multicenter genetic association study. Mol Psychiatry 10:598-605.
22. Ohara K, Nagai M, Suzuki Y, Ohara K. 1998. Low activity allele of catechol-O-methyltransferase gene and Japanese unipolar depression. Neuroreport 9:1305-1308.
23. Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L, Hortobagyi GN. 2004. Pharmacogenomics. Adv Anat Pathol 11:211-220.
24. Serretti A, Cusin C, Cristina S, Lorenzi C, Lilli R, Lattuada E, Grieco G, Costa A, Santorelli F, Barale F, Smeraldi E, Nappi G. 2003. Multicentre Italian family-based association study on tyrosine hydroxylase, catechol-O-methyltransferase and Wolfram syndrome 1 polymorphisms in mood disorders. Psychiatr Genet 13:121-126.
25. Szegedi A, Rujescu D, Tadic A, Müller MJ, Kohnen R, Stassen HH, Dahmen N. 2005. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 5:49-53.
26. Tsai SJ, Gau YT, Hong CJ, Liou YJ, Yu YW, Chen TJ. 2009. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 113:183-187.
27. Wahlund B, von Rosen D. 2003.ECTof major depressed patients in relation to biological and clinical variables: A brief overview. Neuropsychopharmacology 28:21-26.
28. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M. 1997. SKID-I, Strukturiertes Klinisches Interview für DSM-IV. Göttingen: Hogrefe.
29. Xie T, Ho SL, Ramsden D. 1999. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol 56:31-38.
30. Yoshida K, Higuchi H, Kamata M, Yoshimoto M, Shimizo T, Hishikawa Y. 1998. Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Prog Neuropsychopharmacol Biol Psychiatry 22:435-444.